February 28, 2023 – Vaginitis and vaginosis are responsible for over 10 million visits per year to physician offices by women in the U.S., making it the most common gynecologic diagnosis in primary care.1
The Xpert® Xpress MVP (multiplex Vaginal panel) test from Cepheid is a new FDA-cleared on-demand PCR test designed to aid clinicians in diagnosing distinct sexually transmitted infections, including bacterial vaginosis (BV), Candida species associated with vulvovaginal candidiasis, and trichomoniasis, that cause overlapping symptoms in women and potential co-occurrence.
“There’s a significant need in the marketplace for this test,” said Cisco Merrill, National Sales Director, Alternate Site for Sunnyvale, Calif.-based Cepheid.
The test is for patients ages 18 and up. Its single sample collection is designed to run on the easy-to-use GeneXpert® systems for increased efficiency and to reduce repeat visits. And its easy-to-use testing provides physicians with same-day results for appropriate treatment the first time. There is less than one minute of hands-on time and results within one hour.
“Patients may present with what’s considered cross infections and will test positive for one or two of these different infection states,” Merrill said. “But if a clinic is only testing specifically for one infection state, something may be missed. So, a patient might not get put on a good treatment plan.”
Read more in the February issue of Repertoire Magazine.